Clinical trial · Observational
Indication to Transplant Patients With High Risk B Cells Lymphoma in Metabolic Complete Remission?
Indication to Transplant Patients With High Risk B Cells Lymphoma in Metabolic Complete Remission After 2 Cycles of Chemotherapy ?
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The autograft of patients with prognostically unfavourable B-cells lymphoma cells in first remission remains controversial, in particular since the association of Rituximab with chemotherapy. Even though many randomized and non-randomized studies have been conducted, their is still no standard procedure . Recently, the use of early TEP (positron emission topography) answer, after 2 in 3 cures of chemotherapy allowed to select the poor-responder patients who remain candidate to autograft in front-line. Nevertheless, in good-responder patients, the benefits of an intensification therapy ins term of long-lasting disease control remains discussion. This institutional retrospective study aims at comparing the outcome of early metabolic responder patients who received an intensification treatment to those who received a standard chemotherapy.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Lymphoma, B-Cell | B-Cell Malignant Neoplasm | CURATED_BROADER | 0.80 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Autograft | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- label
- Intensification treatment: Autograft
- interventionNames
- Procedure: Autograft
- label
- Standard chemotherapy (without autograft)
Primary outcomes (1)
- measure
- Compare the survival without progress of transplanted patients versus not transplanted patients
- timeFrame
- From the date of complete remission post C2 of chemotherapy up to 120 months
- description
- Medical follow up
Secondary outcomes (2)
- measure
- Cumulative Relapse Incidence
- timeFrame
- From the date of complete remission post C2 of chemotherapy up to 120 months
- description
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Patients with High Risk Big B Cells Lymphoma * Age \> 18 years Exclusion Criteria: * Not applicable
References
Publications (0)
Data not yet available